Hochdosiertes Medroxyprogesteronacetat beim metastasierenden Mammakarzinom: Beziehung zwischen Krankheitsverlauf und Hormonprofilen
- 1 June 1983
- journal article
- clinical trial
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 61 (11) , 553-560
- https://doi.org/10.1007/bf01486845
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncologyCancer Chemotherapy and Pharmacology, 1982
- The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancerCancer Chemotherapy and Pharmacology, 1982
- Medroxyprogesteronacetat in hoher Dosierung beim metastasierenden MammakarzinomOncology Research and Treatment, 1982
- Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancerBreast Cancer Research and Treatment, 1981
- High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapyCancer Chemotherapy and Pharmacology, 1979
- Die hochdosierte Gestagenbehandlung in der Therapie des fortgeschrittenen MammakarzinomsOncology Research and Treatment, 1979
- Steroid structure and function—II. Conformational transmission and receptor binding of medroxyprogesterone acetateThe Journal of Steroid Biochemistry and Molecular Biology, 1978
- Recurrent breast cancer treated with the antioestrogen tamoxifen: correlation between hormonal changes and clinical course.BMJ, 1977
- The Effect of Medroxyprogesterone Acetate on the Pituitary-Adrenal AxisJournal of Clinical Endocrinology & Metabolism, 1976
- GLC Determination of Medroxyprogesterone Acetate in PlasmaJournal of Pharmaceutical Sciences, 1974